GSK Temporarily Pulls sNDA For Avodart
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.
You may also be interested in...
GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.
GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.
GSK Launches Plus Reduced Generic Exposure Will Boost U.S. Sales Ahead, Says CEO Witty
Products currently pending at FDA include Cervarix vaccine, Rezonic anti-emetic, Lamictal XR for epilepsy and Duodart fixed-dose combo.